Crescent Biopharma Inc Dossier
Qualitative Analysis
Business overview
Crescent Biopharma, Inc. (NASDAQ: CBIO) is a clinical-stage biotechnology company dedicated to rapidly advancing next-generation oncology therapeutics. The company was established in its current public form in June 2025 following a transformational reverse merger with GlycoMimetics, Inc., alongside a concurrent $200 million private placement financing and subsequent redomestication to the Cayman Islands. Crescent's pipeline is anchored by its lead program, CR-001 (also known as SKB118), a tetravalent bispecific antibody targeting PD-1 and VEGF. This lead asset is designed to replicate the validated pharmacology of ivonescimab to address advanced solid tumors. Additionally, the company is developing a robust pipeline of novel antibody-drug conjugates (ADCs) with topoisomerase inhibitor payloads, including CR-002 (targeting PD-L1) and CR-003 (targeting ITGB6), both as monotherapies and in combination with CR-001.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing CR-001, a tetravalent PD-1 x VEGF bispecific antibody, through global clinical trials (specifically the Phase 1/2 ASCEND trial) as a foundational backbone therapy for solid tumors.
Expected impact: Aims to replicate the cooperative pharmacology of clinically validated approaches (such as ivonescimab) to deliver superior anti-tumor efficacy.
Building a robust portfolio of antibody-drug conjugates (ADCs) with topoisomerase inhibitor payloads, specifically CR-002 (targeting PD-L1) and CR-003 (targeting ITGB6), to be developed as monotherapies and in synergistic combinations with CR-001.
Expected impact: Establishes a multi-modality oncology pipeline capable of addressing diverse solid tumor indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Crescent Biopharma completed a reverse merger with GlycoMimetics, Inc., enabling Crescent to become a publicly traded company on Nasdaq. Concurrent with the merger, Crescent closed a $200 million private financing round to fund its clinical pipeline through 2027.
Financial impact: The combined company began trading on Nasdaq on June 16, 2025, with a significantly strengthened balance sheet to support clinical operations.
Strategic Partnerships
Crescent secured exclusive rights to develop and commercialize CR-003 (SKB105), an ITGB6-targeted ADC, in global territories outside of Greater China, while Kelun-Biotech secured rights to develop and commercialize CR-001 in Greater China. This enables parallel global clinical development and provides Crescent with a clinical-stage ADC asset.
Terms: Crescent paid an upfront fee of $80 million to Kelun-Biotech and is eligible to pay up to $1.25 billion in development and commercial milestones, plus tiered royalties on SKB105 sales. Kelun-Biotech paid Crescent an upfront fee of $20 million and is eligible to pay up to $30 million in milestones, plus tiered royalties on CR-001 sales in Greater China.